AlphaStocks
6.2
Consider Buy

Organon & Co. (OGN)

As of Sep 20, 2026, Organon & Co. (OGN) scores 6.2/10 on AlphaStocks' five-model composite, #42 of 168 Health Care stocks.

Health Care / Pharmaceuticals

S&P SmallCap 600

$13.69

Middle of the pack. No strong signal either way.

Consider Buy

Score based on 4 of 5 models — moderate confidence

Data as of Sep 20, 2026

#42out of 168 in Health Care

Is Organon & Co. a Good Investment in 2026?

Organon & Co. (OGN) scores 6.2 out of 10 on AlphaStocks' composite model, earning a Consider Buy rating. The Greenblatt Magic Formula model rates Organon & Co. as Strong (Earnings yield 8.0% · ROC 28%). However, the Lynch model rates it Caution. Organon & Co. ranks #42 out of 168 stocks in the Health Care sector.

This summary is algorithmically generated and is not financial advice.

Key Metrics

P/E19.1ROE15.4Market Cap4BDiv Yield2.5

Valuation

Trades at 19x earnings — near sector median of 30x.

Fair value estimate not available for this stock.

5-Model Analysis

Each model evaluates this stock from a different angle. Combined, they form the composite score above.

Piotroski

Attractive

5/9

Buffett

Neutral

Business quality & competitive moat

Graham

Caution

63% above fair value

Lynch

Caution

Growth rate vs price (PEG)

Greenblatt

Strong

Earnings yield 8.0% · ROC 28%

Frequently Asked Questions

Is Organon & Co. (OGN) a good investment?
As of Sep 20, 2026, Organon & Co. (OGN) scores 6.2/10 on AlphaStocks' five-model composite, #42 of 168 Health Care stocks. That is a middle-of-the-pack score with no strong signal either way. Trades at 19x earnings — near sector median of 30x.
What is Organon & Co.'s Piotroski F-Score?
Organon & Co.'s Piotroski F-Score status is Attractive. The raw score is 5/9. The Piotroski F-Score evaluates financial health using 9 fundamental signals including profitability, leverage, and operating efficiency.
Is OGN overvalued or undervalued?
A precise fair value estimate is not available for OGN. Trades at 19x earnings — near sector median of 30x.
How does OGN compare to other Health Care stocks?
Organon & Co. ranks #42 out of 168 stocks in the Health Care sector, placing it in the top 25% of its sector by composite score. This is a strong position relative to sector peers.
What do investment models say about OGN?
AlphaStocks evaluates OGN using five proven investment models. Piotroski: Attractive; Buffett: Neutral; Graham: Caution; Lynch: Caution; Greenblatt Magic Formula: Strong. These models are combined into a single composite score of 6.2/10.

Similar Stocks

AMPHLLYACAD

Compare OGN with

AMPH vs OGNLLY vs OGNACAD vs OGNOGN vs VAL

Scores are algorithm-generated research tools, not investment recommendations. Past performance does not guarantee future results. Always do your own due diligence. Full disclaimer